Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With Chemotherapy or Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
NCT07407452Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706 in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 cohorts), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Adverse Events at 9 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07407452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407452.